North Normandy Drive
About Civica Rx
Because patients should have the essential medicines they need when they need them. As a rapidly growing, entrepreneurial, nonprofit generic drug company created by hospital systems and philanthropies, Civica’s mission is to reduce and prevent drug shortages while assuring quality generic medicines are accessible and affordable to everyone.
WHO CIVICA SERVES
While serving 50 health systems and 1,350 hospitals (or 30% of all licensed U.S. hospital beds), Civica also supplies the U.S. Department of Veterans Affairs, the U.S. Department of Defense, and “340B” hospitals caring for vulnerable patients in some of the country’s most underserved areas. And recently, Civica contributed more than 2-million vials of essential medications to the strategic national stockpile. With 40 sterile injectable medications under contract to supply our member hospitals, Civica is growing and on track to have 100 drugs available by 2023.
Civica Rx is a rapidly growing, entrepreneurial, nonprofit generic drug company created by hospital systems and philanthropies, Civica’s mission is to reduce and prevent drug shortages while assuring quality generic medicines are accessible and affordable to everyone. Videos include comments from Civica's CEO, a Civica Health System leader and a Director of Manufacturing.
13 articles about Civica Rx
Civica Inc. announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins.
Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.
For the 37.3 million Americans who have diabetes, insulin has become increasingly expensive. Here are four organizations dedicated to making insulin more accessible.
Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
Alcami, a leading United States-based contract development and manufacturing organization, announced that it is partnering with Civica Inc., a nonprofit pharmaceutical company focused on ensuring quality generic medicines are accessible and affordable to everyone.
Civica plans to make versions of three affordable insulins available at significantly reduced costs by 2024. You can explore the other aspirations here in this article.
At this time, Civica plans a recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges. It believes it can have these versions of insulin available by 2024.
Civica, Inc. (Civica, Civica Rx) today announced plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at significantly lower prices than insulins currently on the market.
CivicaScript, the Newly Named Civica Initiative to Serve Patients in Retail Markets, Announces a New Health Plan Partner, a New President, and a New Drug Manufacturing Partner
Civica Rx announced that CivicaScript is the name for its operating unit dedicated to lowering the cost of select high-cost generic medicines, and that one of the nation’s largest health insurers and a leading drug manufacturer are joining the initiative.
STATEMENT: Civica Rx Supports Biden Administration Recommendations for Strengthening the Pharmaceutical Supply Chain
Civica Rx welcomes the findings of the 100-day supply chain review. The report identifies key vulnerabilities in the generic drug supply chain that contribute to drug shortages and supply risks during a global public health emergency.
Fueled by billions of dollars invested by the federal government to battle the ongoing COVID-19 pandemic, companies across the BioCapital region have expanded their footprint and number of employees.
The new facility, part of a partnership with Virginia-based Phlow Corp., will employ more than 180 people and will help ensure a safe, stable, and affordable supply of essential generic medicines for U.S. patients